文献速递临床试验与 GCP基础与转化研究

Praliciguat对射血分数保留型心力衰竭患者峰值耗氧量的影响:CAPACITY HFpEF随机临床试验

Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

CAPACITY HFpEF是一项随机双盲安慰剂对照2期试验,纳入196例射血分数≥40%且峰值耗氧量受损、至少合并2项一氧化氮缺乏相关疾病的心衰患者。12周praliciguat 40 mg/d与安慰剂相比未显著改善峰值耗氧量,次要终点亦无统计学意义,不支持该药用于HFpEF。

要点

  • praliciguat 40 mg/d治疗12周未改善HFpEF患者峰值耗氧量。
  • 6分钟步行距离与通气效率等次要终点均无统计学显著差异。
  • praliciguat组头晕、低血压和头痛等不良事件发生率高于安慰剂组。

核心结论

  • 在HFpEF患者中,与安慰剂相比,可溶性鸟苷酸环化酶刺激剂praliciguat未显著改善从基线至第12周的峰值耗氧量。
  • 这些发现不支持praliciguat用于HFpEF患者。

研究设计与样本

  • 纳入标准为心力衰竭且射血分数至少40%、峰值耗氧量受损、至少合并2项与一氧化氮缺乏相关的疾病(糖尿病、高血压、肥胖或高龄)。
  • 试验早期调整为重点比较praliciguat 40 mg组与安慰剂组,最终分析纳入181例完成至少8周指定给药的患者。
  • 患者随机接受每日40 mg praliciguat(n=91)或安慰剂(n=90)治疗12周。

主要发现

  • 安慰剂组(n=78)峰值耗氧量变化为0.04 mL/kg/min(95%CI -0.49至0.56),praliciguat组(n=65)为-0.26 mL/kg/min(95%CI -0.83至0.31)。
  • 3个预设次要终点均无统计学显著性。
  • 安慰剂组与praliciguat组6分钟步行距离变化分别为58.1 m(95%CI 26.1-90.1)和41.4 m(95%CI 8.2-74.5),安慰剂校正组间差异为-16.7 m(95%CI -47.4至13.9)。
  • 通气/二氧化碳产生斜率变化的安慰剂校正组间差异为-0.3(95%CI -1.6至1.0)。

关键数值与推荐

  • 主要疗效终点为完成至少8周指定给药患者峰值耗氧量自基线的变化。
  • 次要终点包括6分钟步行距离和通气效率(通气/二氧化碳产生斜率)自基线的变化。
  • 主要不良事件终点为治疗中出现的不良事件(TEAE)发生率。
  • praliciguat组与安慰剂组相比,头晕(9.9% vs 1.1%)、低血压(8.8% vs 0%)和头痛(11% vs 6.7%)TEAE更常见。
  • 严重TEAE频率两组相似(praliciguat组10%,安慰剂组11%)。

临床怎么用

  • 现有证据不支持在HFpEF患者中使用praliciguat改善峰值耗氧量。
  • 使用praliciguat时需关注头晕、低血压和头痛等不良事件。

局限性

  • 试验早期调整为重点比较40 mg praliciguat与安慰剂,其他剂量组未纳入最终比较。
  • 主要疗效分析仅纳入完成至少8周指定给药的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Heart failure with preserved ejection fraction (HFpEF) is often characterized by nitric oxide deficiency. OBJECTIVE: To evaluate the efficacy and adverse effects of praliciguat, an oral soluble guanylate cyclase stimulator, in patients with HFpEF. DESIGN, SETTING, AND PARTICIPANTS: CAPACITY HFpEF was a randomized, double-blind, placebo-controlled, phase 2 trial. Fifty-nine sites enrolled 196 patients with heart failure and an ejection fraction of at least 40%, impaired peak rate of oxygen consumption (peak V̇o2), and at least 2 conditions associated with nitric oxide deficiency (diabetes, hypertension, obesity, or advanced age). The trial randomized patients to 1 of 3 praliciguat dose groups or a placebo group, but was refocused early to a comparison of the 40-mg praliciguat dose vs placebo. Participants were enrolled from November 15, 2017, to April 30, 2019, with final follow-up on August 19, 2019. INTERVENTIONS: Patients were randomized to receive 12 weeks of treatment with 40 mg of praliciguat daily (n = 91) or placebo (n = 90). MAIN OUTCOMES AND MEASURES: The primary efficacy end point was the change from baseline in peak V̇o2 in patients who completed at least 8 weeks of assigned dosing. Secondary end points included the change from baseline in 6-minute walk test distance and in ventilatory efficiency (ventilation/carbon dioxide production slope). The primary adverse event end point was the incidence of treatment-emergent adverse events (TEAEs). RESULTS: Among 181 patients (mean [SD] age, 70 [9] years; 75 [41%] women), 155 (86%) completed the trial. In the placebo (n = 78) and praliciguat (n = 65) groups, changes in peak V̇o2 were 0.04 mL/kg/min (95% CI, -0.49 to 0.56) and -0.26 mL/kg/min (95% CI, -0.83 to 0.31), respectively; the placebo-adjusted least-squares between-group difference in mean change from baseline was -0.30 mL/kg/min ([95% CI, -0.95 to 0.35]; P = .37). None of the 3 prespecified secondary end points were statistically significant. In the placebo and praliciguat groups, changes in 6-minute walk test distance were 58.1 m (95% CI, 26.1-90.1) and 41.4 m (95% CI, 8.2-74.5), respectively; the placebo-adjusted least-squares between-group difference in mean change from baseline was -16.7 m (95% CI, -47.4 to 13.9). In the placebo and praliciguat groups, the placebo-adjusted least-squares between-group difference in mean change in ventilation/carbon dioxide production slope was -0.3 (95% CI, -1.6 to 1.0). There were more dizziness (9.9% vs 1.1%), hypotension (8.8% vs 0%), and headache (11% vs 6.7%) TEAEs with praliciguat compared with placebo. The frequency of serious TEAEs was similar between the groups (10% in the praliciguat group and 11% in the placebo group). CONCLUSIONS AND RELEVANCE: Among patients with HFpEF, the soluble guanylate cyclase stimulator praliciguat, compared with placebo, did not significantly improve peak V̇o2 from baseline to week 12. These findings do not support the use of praliciguat in patients with HFpEF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03254485.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Udelson JE, Lewis GD, Shah SJ, et al. Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial. JAMA. 2020. PMID: 33079154. doi:10.1001/jama.2020.16641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。